The latest U.S. drug sales data has been released by Drugs.com. Since Q2 2012, Otuska’s antipsychotic Abilify and AstraZeneca’s acid reducer Nexium have held either the number one or two spot in top dollar sales. This quarter, both agents continue to maintain their stronghold; each post close to $1.5 billion in sales. Humira, AbbVie’s key tumor necrosis factor (TNF) blocker, climbs three notches and sees a double-digit gain for the quarter. Biogen Idec’s Avonex Pen and Avonex take a double hit this quarter and lose $187 million in sales.
View the data here…
https://www.drugs.com/stats/top100/sales